Nektar Therapeutics (NKTR) Misses Q1 EPS by 6c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $65.70 +7.74%
Revenue Growth %: -7.1%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -7.1%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $19.8 million versus the consensus estimate of $38.68 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- FedEx (FDX) PT Lowered to $424 at Bernstein SocGen Group
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
